Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 2/20 | 0.41 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 4/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382749 | 0.87 | DGAT1 (0.49) | DGAT1SLC6A7IKBKBJAK2JAK3 | |
| SCHEMBL4377891 | 0.79 | DGAT1 (0.51) | DGAT1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL3764395 | 0.78 | JAK2 (0.68) | DGAT1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL12753480 | 0.69 | HSD11B1 (0.57) | SLC6A7KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL3470744 | 0.67 | IKBKB (0.54) | DGAT1IKBKBMEN1KMT2ACHUK | |
| SCHEMBL3647354 | 0.66 | CYP11B2 (0.58) | DGAT1IKBKBJUNMAPK8MAPK9 | |
| SCHEMBL26457726 | 0.66 | AURKA (0.57) | JAK2 | |
| SCHEMBL1032457 | 0.66 | NOS3 (0.55) | IKBKBMEN1KMT2ACYP2C9JUN | |
| SCHEMBL4135859 | 0.65 | TRPV1 (0.43) | MEN1KMT2AJUNMAPK8MAPK9 | |
| SCHEMBL3652017 | 0.65 | HDAC8 (0.55) | IKBKBJUNMAPK8MAPK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1979329-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | DGAT1 3230/4885SLC6A7 2946/4885IKBKB 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.